Biotech Values

[DewDiligence]

Roche’s Lucentis-eluting implant—refilled every 6mo—shows non-inferior visual acuity compared to regular monthly Lucentis injections in patients with wet AMD:

https://www.businesswire.com/news/home/20200722005151/en

The mean BCVA change from baseline was 0.2 letters in the implant arm and 0.5 letters in the Lucentis-injection arm, which met the pre-specified non-inferiority threshold. (clinicaltrials.gov listing: https://clinicaltrials.gov/ct2/show/NCT03677934 .)

Roche plans to submit applications for marketing to the FDA and EMA.